

Wright Medical Group N.V.
Reconciliation of Non-GAAP Combined Pro Forma Net Sales to Net Sales
(dollars in thousands--unaudited)

	Three months ended			
	September 30, 2015			
	Standalone Wright Medical Group, Inc.	Standalone Tornier N.V., recast ⁽¹⁾	Discontinued net sales ⁽²⁾	Non-GAAP combined pro forma net sales
U.S.				
Lower extremities	\$ 43,929	\$ 8,675	\$ (2,905)	\$ 49,699
Upper extremities	3,654	37,908	—	41,562
Biologics	12,198	412	—	12,610
Sports med & other	613	1,810	—	2,423
Total extremities & biologics	60,394	48,805	(2,905)	106,294
Large joint	—	33	(33)	—
Total U.S.	\$ 60,394	\$ 48,838	\$ (2,938)	\$ 106,294
International				
Lower extremities	\$ 10,917	\$ 2,275	\$ —	\$ 13,192
Upper extremities	1,764	14,862	—	16,626
Biologics	5,260	114	—	5,374
Sports med & other	1,804	1,505	—	3,309
Total extremities & biologics	19,745	18,756	—	38,501
Large joint	—	7,350	(7,350)	—
Total International	\$ 19,745	\$ 26,106	\$ (7,350)	\$ 38,501
Global				
Lower extremities	\$ 54,846	\$ 10,950	\$ (2,905)	\$ 62,891
Upper extremities	5,418	52,770	—	58,188
Biologics	17,458	526	—	17,984
Sports med & other	2,417	3,315	—	5,732
Total extremities & biologics	80,139	67,561	(2,905)	144,795
Large joint	—	7,383	(7,383)	—
Total net sales	\$ 80,139	\$ 74,944	\$ (10,288)	\$ 144,795

(1) Legacy Tornier product line sales have been recast to reflect the reclassification of cement, instruments and freight from the historical Tornier product line "Large Joints and Other" to the product line associated with those revenues that will be utilized for future revenue reporting.

(2) To reduce from Tornier's historical sales the U.S. sales associated with Tornier's Salto Talaris and Salto XT ankle replacement products and silastic toe replacement products and the global sales associated with Tornier's Large Joint business.

Wright Medical Group N.V.
Reconciliation of Non-GAAP Combined Pro Forma Net Sales to Net Sales
(dollars in thousands--unaudited)

	Nine months ended			
	September 30, 2015			
	Standalone Wright Medical Group, Inc.	Standalone Tornier N.V., recast ⁽¹⁾	Discontinued net sales ⁽²⁾	Non-GAAP combined pro forma net sales
U.S.				
Lower extremities	128,277	29,636	(9,732)	148,181
Upper extremities	11,703	115,846	—	127,549
Biologics	34,612	1,290	—	35,902
Sports med & other	1,558	5,021	—	6,579
Total extremities & biologics	176,150	151,793	(9,732)	318,211
Large joint	—	119	(119)	—
Total U.S.	\$ 176,150	\$ 151,912	\$ (9,851)	\$ 318,211
International				
Lower extremities	35,313	7,402	—	42,715
Upper extremities	5,723	51,293	—	57,016
Biologics	15,070	357	—	15,427
Sports med & other	6,237	5,372	—	11,609
Total extremities & biologics	62,343	64,424	—	126,767
Large joint	—	29,921	(29,921)	—
Total International	\$ 62,343	\$ 94,345	\$ (29,921)	\$ 126,767
Global				
Lower extremities	163,590	37,038	(9,732)	190,896
Upper extremities	17,426	167,139	—	184,565
Biologics	49,682	1,647	—	51,329
Sports med & other	7,795	10,393	—	18,188
Total extremities & biologics	238,493	216,217	(9,732)	444,978
Large joint	—	30,040	(30,040)	—
Total sales	\$ 238,493	\$ 246,257	\$ (39,772)	\$ 444,978

⁽¹⁾ Legacy Tornier product line sales have been recast to reflect the reclassification of cement, instruments and freight from the historical Tornier product line "Large Joints and Other" to the product line associated with those revenues that will be utilized for future revenue reporting.

⁽²⁾ To reduce from Tornier's historical sales the U.S. sales associated with Tornier's Salto Talaris and Salto XT ankle replacement products and silastic toe replacement products and the global sales associated with Tornier's Large Joint business.

Wright Medical Group N.V.
Supplemental Combined Pro Forma Net Sales Information
(unaudited)

Third Quarter 2016 net sales growth/(decline)

Product line	U.S. combined pro forma	Int'l combined pro forma constant currency	Int'l combined pro forma	Global combined pro forma constant currency	Global combined pro forma
Lower extremities	4%	11%	8%	5%	5%
Upper extremities	11%	5%	4%	9%	9%
Biologics	45%	(10%)	(12%)	28%	28%
Sports med & other	(16%)	(5%)	(9%)	(10%)	(12%)
Total net sales	11%	4%	2%	9%	9%

Nine months ended September 25, 2016 net sales growth/(decline)

Product line	U.S. combined pro forma	Int'l combined pro forma constant currency	Int'l combined pro forma	Global combined pro forma constant currency	Global combined pro forma
Lower extremities	7%	11%	8%	8%	7%
Upper extremities	15%	11%	9%	13%	13%
Biologics	48%	(7%)	(11%)	31%	30%
Sports med & other	(4%)	(4%)	(7%)	(4%)	(6%)
Total net sales	15%	7%	5%	12%	12%

Wright Medical Group N.V.
Reconciliation of Non-GAAP Adjusted Gross Margins to Gross Margins from Continuing Operations
(dollars in thousands--unaudited)

	Three months ended	Nine months ended
	September 25, 2016	September 25, 2016
Gross profit from continuing operations, as reported	\$ 111,183	\$ 355,515
Gross margins from continuing operations, as reported	70.7 %	71.5 %
Reconciling items impacting gross profit:		
Inventory step-up amortization	10,306	30,922
Product rationalization	1,573	3,527
Transaction and transition costs	—	124
Non-GAAP gross profit from continuing operations, as adjusted	\$ 123,062	\$ 390,088
Net sales from continuing operations	157,332	497,339
Non-GAAP adjusted gross margins from continuing operations	78.2%	78.4%

Wright Medical Group N.V.
Reconciliation of Adjusted Non-GAAP Earnings Per Share to Net Loss from Continuing Operations Per Share
(dollars in thousands, except per share data--unaudited)

	Three months ended	Nine months ended
	September 25, 2016	September 25, 2016
Net loss from continuing operations, as reported	\$ (52,709)	\$ (134,932)
Net loss from continuing operations per share, as reported	\$ (0.51)	\$ (1.31)
Reconciling items:		
Inventory step-up amortization ⁽¹⁾	10,306	30,922
Product rationalization ⁽¹⁾	1,573	3,527
Non-cash interest expense on convertible notes	10,516	25,812
Non-cash loss on extinguishment of debt	—	12,343
Derivatives mark-to-market adjustments	(3,187)	(26,460)
Transaction and transition costs ⁽³⁾	6,532	24,425
Management changes ⁽²⁾	—	1,348
CVR mark-to-market adjustments	2,243	8,968
Contingent consideration fair value adjustment	70	376
Legal settlement ⁽²⁾	—	1,800
Costs associated with new convertible debt ⁽²⁾	—	234
IRS settlement ⁽⁴⁾	—	(3,073)
Tax effect of reconciling items	(2,313)	(5,634)
Non-GAAP net loss from continuing operations, as adjusted	\$ (26,969)	\$ (60,344)
Add back amortization of intangible assets	7,466	21,407
Adjusted non-GAAP earnings	\$ (19,503)	\$ (38,937)
Weighted-average basic shares outstanding	103,072	102,854
Adjusted non-GAAP earnings per share	\$ (0.19)	\$ (0.38)

⁽¹⁾ Impacting gross profit.

⁽²⁾ Impacting selling, general, and administrative expense.

⁽³⁾ Impacting selling, general, and administrative expense and research and development expense for \$6.4 million and \$0.2 million, respectively, for the three months ended September 25, 2016. Impacting gross profit; selling, general, and administrative expense; and research and development expense for \$0.1 million, \$23.9 million, and \$0.4 million, respectively, for the nine months ended September 25, 2016.

⁽⁴⁾ IRS settlement includes \$0.8 million of interest income and \$2.3 million tax benefit.

Wright Medical Group N.V.
Reconciliation of Non-GAAP Adjusted EBITDA to Net Loss from Continuing Operations
(dollars in thousands--unaudited)

	Three months ended	Nine months ended
	September 25, 2016	September 25, 2016
Net loss from continuing operations	\$ (52,709)	\$ (134,932)
Interest expense, net	16,795	41,673
Benefit from income taxes	(2,325)	(6,913)
Depreciation	14,885	41,005
Amortization	7,466	21,407
Non-GAAP EBITDA	\$ (15,888)	\$ (37,760)
Reconciling items impacting EBITDA:		
Non-cash share-based compensation expense	3,528	9,901
Other income, net	(365)	(3,494)
Inventory step-up amortization	10,306	30,922
Product rationalization	1,573	3,527
Transaction and transition costs	6,532	24,425
Management changes	—	1,348
Legal settlement	—	1,800
Costs associated with new convertible debt	—	234
Non-GAAP adjusted EBITDA	\$ 5,686	\$ 30,903
Net sales from continuing operations	157,332	497,339
Non-GAAP adjusted EBITDA margin	3.6%	6.2%

Wright Medical Group N.V.
Reconciliation of Other Non-GAAP Financial Measures to Other As Reported Results
(dollars in thousands--unaudited)

	Three months ended	Nine months ended
	September 25, 2016	September 25, 2016
Net sales	\$ 157,332	\$ 497,339
Selling, general and administrative expense, as reported	\$ 129,840	\$ 401,069
Selling, general and administrative expense as a percentage of net sales, as reported	82.5 %	80.6 %
Reconciling items impacting selling, general and administrative expense:		
Transaction and transition costs - selling, general and administrative	6,382	23,912
Management changes	—	1,348
Legal settlement	—	1,800
Costs associated with new convertible debt	—	234
Selling, general and administrative expense, as adjusted	\$ 123,458	\$ 373,775
Selling, general and administrative expense as a percentage of net sales, as adjusted	78.5%	75.2%
Research & development expense, as reported	\$ 12,481	\$ 36,705
Research & development expense as a percentage of net sales, as reported	7.9 %	7.4 %
Reconciling items impacting research & development expense:		
Transaction and transition costs - research & development	150	389
Research & development expense, as adjusted	\$ 12,331	\$ 36,316
Research & development expense as a percentage of net sales, as adjusted	7.8%	7.3%